KR20000076157A
(ko)
*
|
1997-03-11 |
2000-12-26 |
리전츠 오브 더 유니버스티 오브 미네소타 |
세포의 디엔에이로 핵산을 도입하는 디엔에이-기초 전이인자 시스템
|
CA2309000A1
(en)
*
|
1997-11-13 |
1999-05-27 |
Regents Of The University Of Minnesota |
Tc1-based transposon vectors
|
US7160682B2
(en)
*
|
1998-11-13 |
2007-01-09 |
Regents Of The University Of Minnesota |
Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
|
EP1155131B1
(de)
*
|
1999-02-19 |
2008-07-23 |
ABT Holding Company |
Vektor mit einer splice acceptor trap und einer poly a trap und entsprechende eukaryotische wirtszellen
|
US6299850B1
(en)
|
1999-03-16 |
2001-10-09 |
The United States Of America As Represented By The Department Of Energy |
Carbon activation process for increased surface accessibility in electrochemical capacitors
|
US6562624B2
(en)
|
1999-03-17 |
2003-05-13 |
Paradigm Genetics, Inc. |
Methods and materials for the rapid and high volume production of a gene knock-out library in an organism
|
JP2002543792A
(ja)
*
|
1999-05-11 |
2002-12-24 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
ベクターによるトランスポゾン配列の供給及び組込み
|
US7196244B1
(en)
*
|
1999-06-01 |
2007-03-27 |
University Of Utah |
Method of transposon-mediated mutagenesis in the nematode caenorhabditis elegans
|
WO2001029205A2
(en)
*
|
1999-10-19 |
2001-04-26 |
Minos Biosystems Limited |
Method for genetic manipulation
|
AU7900300A
(en)
*
|
1999-10-26 |
2001-05-08 |
Shanghai Bio Road Gene Development Ltd. |
A novel polypeptide - human pogo transposase 14 and a polynucleotide encoding the same
|
AU1100201A
(en)
*
|
1999-10-28 |
2001-05-08 |
Board Of Trustees Of The Leland Stanford Junior University |
Methods of in vivo gene transfer using a sleeping beauty transposon system
|
CN1300827A
(zh)
*
|
1999-12-22 |
2001-06-27 |
上海博德基因开发有限公司 |
一种新的多肽—人水手转座酶19和编码这种多肽的多核苷酸
|
JP2001231567A
(ja)
*
|
2000-02-18 |
2001-08-28 |
Inst Of Physical & Chemical Res |
テロメア長の調節方法
|
AU2001247244B2
(en)
*
|
2000-02-28 |
2005-06-02 |
Genesegues, Inc. |
Nanocapsule encapsulation system and method
|
AU2001265756A1
(en)
*
|
2000-04-27 |
2001-11-07 |
Max-Delbruck-Centrum Fur Molekulare Medizin |
Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
|
AU2002256304A1
(en)
*
|
2001-04-20 |
2002-11-05 |
Srilalitha Belur |
Compositions for delivery of compounds to cells and methods of use
|
EP1308516A1
(de)
*
|
2001-10-24 |
2003-05-07 |
ADEREGEM (Association pour le Développement de la Recherche en Génétique Moléculaire |
Zielgerichtete Rekombinase-Fusionsproteine und entsprechende Polynukleotide, Vektoren und Kits, und deren Verwendungen zur zielgerichteten DNS-Rekombination
|
WO2003089618A2
(en)
|
2002-04-22 |
2003-10-30 |
Regents Of The University Of Minnesota |
Transposon system and methods of use
|
US7164056B2
(en)
|
2002-05-03 |
2007-01-16 |
Pioneer Hi-Bred International, Inc. |
Gene targeting using replicating DNA molecules
|
DE10224242A1
(de)
*
|
2002-05-29 |
2003-12-11 |
Max Delbrueck Centrum |
Frog Prince, ein Transposonvektor für den Gentransfer bei Wirbeltieren
|
US7527966B2
(en)
*
|
2002-06-26 |
2009-05-05 |
Transgenrx, Inc. |
Gene regulation in transgenic animals using a transposon-based vector
|
US20040172667A1
(en)
*
|
2002-06-26 |
2004-09-02 |
Cooper Richard K. |
Administration of transposon-based vectors to reproductive organs
|
EP1380289A1
(de)
*
|
2002-07-10 |
2004-01-14 |
Denis Bron |
Verabreichungsform für pharmazeutische Agenzien
|
TW200411052A
(en)
*
|
2002-07-12 |
2004-07-01 |
Takara Bio Inc |
Method of transferring mutation into target nucleic acid
|
US20060236413A1
(en)
*
|
2003-02-10 |
2006-10-19 |
Zoltan Ivics |
Transposon-based targeting system
|
DK1594973T3
(da)
*
|
2003-02-10 |
2012-02-13 |
Max Delbrueck Centrum |
Transposonbaseret målretningssystem
|
WO2004069994A2
(en)
*
|
2003-02-10 |
2004-08-19 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Transposon-based targeting system
|
US7985739B2
(en)
*
|
2003-06-04 |
2011-07-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced sleeping beauty transposon system and methods for using the same
|
WO2005003359A1
(ja)
*
|
2003-07-08 |
2005-01-13 |
Japan Science And Technology Corporation |
トランスジェニック生物を作製する方法およびシステム
|
US7194978B2
(en)
*
|
2003-08-22 |
2007-03-27 |
University Of Maryland Biotechnology Institute |
Inducing sterility in fish by disrupting the development of the GnRH system
|
WO2005062881A2
(en)
|
2003-12-24 |
2005-07-14 |
Transgenrx, Inc. |
Gene therapy using transposon-based vectors
|
US7727744B2
(en)
|
2004-03-30 |
2010-06-01 |
Epicentre Technologies Corporation |
Methods for obtaining directionally truncated polypeptides
|
US20060294606A1
(en)
*
|
2004-05-18 |
2006-12-28 |
Istefo Moisyadi |
Tn5 transposase-mediated transgenesis
|
US20060026699A1
(en)
*
|
2004-06-04 |
2006-02-02 |
Largaespada David A |
Methods and compositions for identification of genomic sequences
|
AU2005299413A1
(en)
|
2004-10-22 |
2006-05-04 |
Revivicor, Inc. |
Ungulates with genetically modified immune systems
|
US7919583B2
(en)
*
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
WO2008005533A2
(en)
*
|
2006-07-06 |
2008-01-10 |
Aaron Thomas Tabor |
Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
|
JP5726522B2
(ja)
*
|
2007-07-04 |
2015-06-03 |
マックス−デルブリュック−ツェントルム フューア モレキュラーレ メディツィン |
トランスポゾンシステム−スリーピングビューティーのトランスポザーゼタンパク質の機能亢進性バリアント
|
DE102007048134A1
(de)
*
|
2007-10-05 |
2009-04-09 |
Evocatal Gmbh |
Verfahren und Gen-Kassetten zur Klonierung, Integration und Expression mehrerer Gene eines Genclusters
|
CA2621155A1
(en)
*
|
2008-02-29 |
2009-08-29 |
James Ellis |
Stem cell expression cassettes
|
US20100105140A1
(en)
*
|
2008-07-16 |
2010-04-29 |
Fahrenkrug Scott C |
Plaice dna transposon system
|
WO2010036979A2
(en)
*
|
2008-09-25 |
2010-04-01 |
Transgenrx, Inc. |
Novel vectors for production of interferon
|
WO2010036978A2
(en)
|
2008-09-25 |
2010-04-01 |
Transgenrx, Inc. |
Novel vectors for production of growth hormone
|
US9150880B2
(en)
|
2008-09-25 |
2015-10-06 |
Proteovec Holding, L.L.C. |
Vectors for production of antibodies
|
WO2010051288A1
(en)
|
2008-10-27 |
2010-05-06 |
Revivicor, Inc. |
Immunocompromised ungulates
|
WO2010083842A2
(en)
|
2009-01-23 |
2010-07-29 |
Nsgene A/S |
Expression of neuropeptides in mammalian cells
|
AU2010206374B2
(en)
|
2009-01-23 |
2013-01-17 |
Gloriana Therapeutics Sarl |
Improved cell lines and their use in encapsulated cell biodelivery
|
WO2010118360A1
(en)
|
2009-04-09 |
2010-10-14 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Production of proteins using transposon-based vectors
|
US8722964B2
(en)
*
|
2009-04-23 |
2014-05-13 |
Transposagen Biopharmaceuticals, Inc. |
Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
|
EP2449112A1
(de)
|
2009-07-01 |
2012-05-09 |
Transposagen Biopharmaceuticals, Inc. |
Genetisch modifizierte rattenmodelle für schwere kombinierte immundefizienz (scid)
|
US8502015B1
(en)
|
2009-07-06 |
2013-08-06 |
Transgenex Nanobiotech, Inc. |
Method of inducing cancer
|
EP2454368A4
(de)
|
2009-07-17 |
2013-01-09 |
Aaron Thomas Tabor |
Zusammensetzungen und verfahren zur genetischen modifizierung von zellen mit kosmetischer funktion zur verbesserung des kosmetischen erscheinungsbilds
|
US8558055B2
(en)
|
2009-07-24 |
2013-10-15 |
Transposagen Biopharmaceuticals, Inc. |
Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease
|
EP2460016A2
(de)
|
2009-07-30 |
2012-06-06 |
Transposagen Biopharmaceuticals, Inc. |
Genetisch modifizierte rattenmodelle für die pharmakokinetik
|
DK2462230T3
(en)
*
|
2009-08-03 |
2015-10-19 |
Recombinetics Inc |
METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION
|
US20110035816A1
(en)
*
|
2009-08-05 |
2011-02-10 |
Ostertag Eric M |
Genetically Modified Rat Models for Drug Metabolism
|
US20120151609A1
(en)
|
2009-08-20 |
2012-06-14 |
Ostertag Eric M |
Genetically Modified Rat Models for Pain
|
US9420770B2
(en)
|
2009-12-01 |
2016-08-23 |
Indiana University Research & Technology Corporation |
Methods of modulating thrombocytopenia and modified transgenic pigs
|
WO2011153440A2
(en)
|
2010-06-04 |
2011-12-08 |
Regents Of The University Of Minnesota |
Transposon mutagenesis system and methods of use
|
RU2447150C1
(ru)
*
|
2010-11-26 |
2012-04-10 |
Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН |
Средство для генной терапии злокачественных опухолей
|
WO2012129198A1
(en)
|
2011-03-23 |
2012-09-27 |
Transposagen Biopharmaceuticals, Inc. |
Genetically modified rat models for obesity and diabetes
|
PT2692865E
(pt)
|
2012-07-30 |
2015-02-06 |
Nbe Therapeutics Llc |
Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
|
KR102095700B1
(ko)
|
2013-05-14 |
2020-04-01 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
가공된 키메라 항원 수용체 (car) t-세포의 인간 적용
|
SG11201509609SA
(en)
|
2013-05-24 |
2015-12-30 |
Univ Texas |
Chimeric antigen receptor-targeting monoclonal antibodies
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR20160101073A
(ko)
|
2013-12-20 |
2016-08-24 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
CA2945388A1
(en)
*
|
2014-04-23 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) for use in therapy and methods for making the same
|
KR20170054429A
(ko)
|
2014-09-03 |
2017-05-17 |
제네세규스 인코포레이티드 |
치료용 나노입자 및 관련 조성물, 방법, 및 시스템
|
US20170333480A1
(en)
|
2014-11-05 |
2017-11-23 |
Board Of Regents, The University Of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
ES2854675T3
(es)
|
2015-03-11 |
2021-09-22 |
Univ Texas |
Polipéptidos de transposasa y usos de los mismos
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
GB201602473D0
(en)
|
2016-02-11 |
2016-03-30 |
Horizon Discovery Ltd |
Replicative transposon system
|
EP3219803A1
(de)
|
2016-03-15 |
2017-09-20 |
Max-Delbrück-Centrum für Molekulare Medizin |
Verbesserte dornröschen-transposone, kits und verfahren für die transposition
|
WO2020047527A2
(en)
|
2018-09-02 |
2020-03-05 |
F1 Bioventures, Llc |
Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
KR102497013B1
(ko)
|
2016-06-07 |
2023-02-20 |
맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 |
Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포
|
JP2019517267A
(ja)
|
2016-06-08 |
2019-06-24 |
イントレキソン コーポレーション |
Cd33特異的キメラ抗原受容体
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
KR20190102259A
(ko)
|
2017-01-10 |
2019-09-03 |
인트렉손 코포레이션 |
신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
|
EP3574116A1
(de)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
|
KR20230119735A
(ko)
|
2017-02-12 |
2023-08-16 |
바이오엔테크 유에스 인크. |
Hla 기반 방법 및 조성물, 및 이들의 용도
|
KR20200003370A
(ko)
|
2017-03-03 |
2020-01-09 |
에프1 온콜로지, 인코포레이티드 |
림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3610266A4
(de)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
Tumorsignatur für metastasen, zusammensetzungen von substanzen und verwendung davon
|
MX2019012398A
(es)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Composiciones para detectar secreciones y metodos de uso.
|
IL306102A
(en)
|
2017-06-07 |
2023-11-01 |
Precigen Inc |
Expression of new cell markers
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
KR20200064060A
(ko)
|
2017-07-29 |
2020-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포 증폭용 시약
|
AU2018321134A1
(en)
|
2017-08-23 |
2020-02-27 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Chimeric antigen receptor and CAR-T cells that bind CXCR5
|
WO2019060746A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
SYSTEMS, METHODS, AND COMPOSITIONS FOR THE TARGETED EDITING OF NUCLEIC ACIDS
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
CA3084514A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
CN111601883A
(zh)
|
2017-11-17 |
2020-08-28 |
艾欧凡斯生物治疗公司 |
由细针抽吸物和小活检物扩增til
|
EP3714041A1
(de)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
|
JP2021505168A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
操作されたt細胞の組成物を製造するための方法
|
KR20200119242A
(ko)
|
2018-01-08 |
2020-10-19 |
이오반스 바이오테라퓨틱스, 인크. |
종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
US11608362B2
(en)
|
2018-03-06 |
2023-03-21 |
Precigen, Inc. |
Hepatitis B vaccines and uses of the same
|
EP3781590A1
(de)
|
2018-04-20 |
2021-02-24 |
Medizinische Hochschule Hannover |
Chimärer antigenrezeptor und car-t zellen, die ein herpesvirus-antigen binden
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
MX2020011134A
(es)
|
2018-04-27 |
2020-11-11 |
Iovance Biotherapeutics Inc |
Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
CN113272420A
(zh)
|
2018-11-05 |
2021-08-17 |
艾欧凡斯生物治疗公司 |
经改进的肿瘤反应性t细胞的选择
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
AU2019374761A1
(en)
|
2018-11-05 |
2021-06-10 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CA3123392A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
WO2020132586A1
(en)
|
2018-12-21 |
2020-06-25 |
Neon Therapeutics, Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
EP3931310A1
(de)
|
2019-03-01 |
2022-01-05 |
Iovance Biotherapeutics, Inc. |
Expansion von tumorinfiltrierenden lymphozyten aus hämatologischen tumoren und therapeutische verwendungen davon
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
WO2020193628A1
(en)
|
2019-03-25 |
2020-10-01 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft |
Enhancement of cytolytic t-cell activity by inhibiting ebag9
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
WO2020245343A1
(en)
|
2019-06-05 |
2020-12-10 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
|
CN114729383A
(zh)
|
2019-07-02 |
2022-07-08 |
弗莱德哈钦森癌症研究中心 |
重组ad35载体及相关基因疗法改进
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
WO2021081378A1
(en)
|
2019-10-25 |
2021-04-29 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
JP2022554348A
(ja)
|
2019-11-05 |
2022-12-28 |
ジュノー セラピューティクス インコーポレイテッド |
治療用t細胞組成物の属性を決定する方法
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
AU2021225817A1
(en)
|
2020-02-24 |
2022-10-20 |
Immatics US, Inc. |
Methods for expanding T cells for the treatment of cancer and related malignancies
|
CN113584083A
(zh)
|
2020-04-30 |
2021-11-02 |
深圳市深研生物科技有限公司 |
用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
|
TW202208617A
(zh)
|
2020-05-04 |
2022-03-01 |
美商艾歐凡斯生物治療公司 |
用於產生腫瘤浸潤性淋巴球的過程及其在免疫療法中的用途
|
EP4146793A1
(de)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Auswahl von verbesserten tumorreaktiven t-zellen
|
WO2021231657A1
(en)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
WO2022043312A1
(en)
|
2020-08-24 |
2022-03-03 |
Charité - Universitätsmedizin Berlin |
Chimeric antigen receptor (car)-expressing cells recognizing cea
|
US20240009310A1
(en)
|
2020-08-24 |
2024-01-11 |
Charité - Universitätsmedizin Berlin |
A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4259164A1
(de)
|
2020-12-11 |
2023-10-18 |
Iovance Biotherapeutics, Inc. |
Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit braf-hemmern und/oder mek-hemmern
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
US20240041927A1
(en)
|
2020-12-22 |
2024-02-08 |
Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) |
Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen
|
EP4019538A1
(de)
|
2020-12-22 |
2022-06-29 |
Charité - Universitätsmedizin Berlin |
Umprogrammierung von immunzellen durch gezielte integration von zeta-defizitären chimären antigen-rezeptor-transgenen
|
WO2022147444A2
(en)
|
2020-12-30 |
2022-07-07 |
Alaunos Therapeutics, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
JP2024506557A
(ja)
|
2021-01-29 |
2024-02-14 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
|
AU2022227085A1
(en)
|
2021-02-25 |
2023-09-14 |
Alaunos Therapeutics, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
WO2022187289A1
(en)
|
2021-03-01 |
2022-09-09 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of retroviral particles
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
EP4314814A1
(de)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Verfahren zur bestimmung der wirksamkeit einer therapeutischen zellzusammensetzung
|
EP4326287A2
(de)
|
2021-04-19 |
2024-02-28 |
Iovance Biotherapeutics, Inc. |
Chimäre kostimulatorische rezeptoren, chemokinrezeptoren und deren verwendung in zellulären immuntherapien
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
TW202328439A
(zh)
|
2021-09-09 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
使用pd-1 talen基因減弱生成til產物之方法
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
GB202117314D0
(en)
|
2021-11-30 |
2022-01-12 |
Clarke David John |
Cyclic nucleic acid fragmentation
|
WO2023122716A1
(en)
|
2021-12-22 |
2023-06-29 |
Vanderbilt University |
Next generation transpososomes
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150562A1
(en)
|
2022-02-01 |
2023-08-10 |
Alaunos Therapeutics, Inc. |
Methods for activation and expansion of t cells
|
WO2023150393A2
(en)
|
2022-02-07 |
2023-08-10 |
Ensoma, Inc. |
Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
|
WO2023168305A1
(en)
|
2022-03-01 |
2023-09-07 |
Exuma Biotech Corp. |
Viral particles with membrane-bound hyaluronidase
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023183344A1
(en)
|
2022-03-21 |
2023-09-28 |
Alaunos Therapeutics, Inc. |
Methods for identifying neoantigen-reactive t cell receptors
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023230272A1
(en)
|
2022-05-27 |
2023-11-30 |
Kite Pharma, Inc. |
Non-viral delivery of cell therapy constructs
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
CN116949092A
(zh)
*
|
2022-09-21 |
2023-10-27 |
上海吉量医药工程有限公司 |
一种转座子系统及其应用
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
EP4353253A1
(de)
|
2022-10-10 |
2024-04-17 |
Charité - Universitätsmedizin Berlin |
Reinigung von tcr-modifizierten t-zellen unter verwendung tcr-spezifischer car-nk-zellen
|